NE Please replace lines 7-9 on page 93 with

SEQ ID NO:1 is the amino acid sequence for HSPDE1B2. For comparative purposes the sequence for HSPDE1B1 (SEQ ID NO:3) is shown in as a comparison using CLUSTAL W (1.74) multiple sequence alignment

NE Please replace lines 3-5 on page 94 with

SEQ ID NO:2 is the nucleotide sequence for HSPDE1B2. For comparative purposes the sequence for HSPDE1B1 (SEQ ID NO:4) is shown in as a comparison using CLUSTAL W (1.74) multiple sequence alignment

In the Claims:

Please amend claims 11, 12, and 16 as follows:

11. (Amended) A method of affecting in vivo PDE1B2 activity ~~or expression~~ with an agent;

wherein the agent is capable of affecting PDE1B2 activity ~~or expression~~ in an in vitro assay method;

wherein the in vitro assay method is the assay method defined in claim 8 ~~or claim 9~~, said method comprising administering said agent to a subject.

B11 12. (Amended) ~~Use of an agent in the preparation of a~~ A pharmaceutical composition for the treatment of a disease or condition associated with PDE1B2 , ~~the agent is~~ said composition comprising an agent capable of having an effect on the activity ~~or expression~~ of PDE when assayed in vitro by the assay method according to claim 8 ~~or claim 9~~.

16. (Amended) ~~Use of an agent which has an effect on the activity of PDE1B2 or the expression thereof in the preparation of a~~ A pharmaceutical composition for the treatment of a disease or condition associated with PDE1B2, said composition comprising an agent which has an effect on the activity of PDE1B2 or the expression thereof.

B12